Selank and Semax Named as Underdiscussed Anxiety and Stress Peptides in Gemelli-Greenfield Discussion
In a podcast on peptide channel takedowns, Dylan Gemelli names Selank and Semax as two peptides he considers underdiscussed, framing them as options for anxiety and stress and citing a family history of anxiety plus dissatisfaction with conventional anxiolytic treatment. He predicts attention will move past GLP-1s toward peptides targeting the mind, heart, liver and kidneys. No dosing, route, cycling, or outcome data is provided, and the speakers state the compounds are discussed for research purposes only. This is opinion and market commentary, not clinical evidence.
Ep.70 - The Benefits and Costs of Stress on The Body
Clinicians discussing chronic stress physiology cite Selank as an early, high-yield intervention for the mental and emotional component of stressed patient presentations. They stress that it works only with correct patient context and sequencing, and note they routinely see it fail when applied outside that context. No dosing, route, or duration given. Clinical opinion within a podcast on stress, cytokine signaling, and neuroendocrine load.
Patient Context and Sequencing as Safety Framework for Peptide and Stress Intervention Use
A key safety and efficacy principle discussed is that peptides (specifically Selank is named) and other stressors must be matched to patient context and sequenced appropriately — they do not work universally and can be counterproductive if applied without this framework. Post-viral patients, nutritionally deficient patients, and those already under high allostatic load are flagged as populations where adding stressors (including peptide interventions) without proper sequencing can cause harm. This is presented as a clinical safety warning.
Selank as an Early-Sequencing Tool to Enable Patient Compliance and Downstream Protocol Adherence
Selank is described as a strategic early-stage intervention that helps patients feel heard and on the right track, which then opens the door to further protocol steps including circadian clock optimization and sleep improvement. The clinical rationale is that addressing the mental/emotional stress pathway first creates a foundation ('game on') for subsequent interventions. No specific dosage or frequency is mentioned in this episode.
Selank Sequencing: Patient Context and Pathway Logic Required for Efficacy
Dr. Seeds notes that Selank does not work universally and that its efficacy is dependent on correct patient selection, proper sequencing within a broader protocol, and alignment with the underlying cellular logic being addressed. Cases where it fails are attributed to improper sequencing or mismatched patient context rather than the peptide itself being ineffective. This implies a contraindication-by-context rather than an absolute contraindication.
Selank for Mental/Emotional Stress and Psychosocial Adaptation
Dr. Seeds recommends Selank as a targeted peptide intervention for patients presenting with significant mental and emotional stress components. It is positioned as an early-sequencing tool within a patient-context-driven protocol to address the psychosocial dimension of allostatic load. The rationale is that by reducing the mental/emotional stress burden first, the patient gains confidence in the treatment approach and becomes more receptive to further interventions. No specific dosage or frequency is mentioned.
Peptide Therapy Must Be Sequenced Within a Broader Cellular Medicine Protocol
A core clinical principle articulated throughout the episode is that peptide therapies should not be introduced in isolation or without regard to patient context, sequencing, and pathway logic. Introducing peptides too early or in the wrong order — particularly in patients who are nutritionally deficient, post-viral, or already under high allostatic load — risks worsening the patient's condition. The speaker frames this as a safety and efficacy principle applicable to all peptide interventions discussed. No specific dosages are mentioned in this context.
Selank Efficacy is Context- and Sequence-Dependent
The speaker explicitly notes that Selank does not always work and that clinical staff have observed cases where it fails to produce the desired effect. This is attributed to improper sequencing, mismatched patient context, or misalignment with the underlying cellular pathway logic being addressed. This constitutes a practical safety/efficacy warning: Selank should not be applied indiscriminately but only when the clinical picture supports its use. No dosage information is provided.
Selank as an Early-Sequencing Tool to Build Patient Trust and Compliance
Selank is described as a strategic early-intervention tool in the clinical sequencing process, used to provide a quick, tangible win for patients who are struggling with stress and mental load. By addressing the mental/emotional pathway early, it helps patients feel heard and builds confidence in the treatment protocol. This in turn opens the door to further interventions such as circadian rhythm optimization and sleep improvement. No dosage is specified.
Selank for Mental/Emotional Stress and Psychosocial Stress Response
Dr. Seeds recommends Selank as a targeted peptide intervention for patients presenting with significant mental and emotional stress components. It is described as having 'an incredible place' in the right clinical circumstances, particularly when the mental/emotional aspect of stress is identified as a primary driver of the patient's condition. The speaker emphasizes that proper patient context, sequencing, and alignment with cellular pathway logic are prerequisites for effective use. No specific dosage or frequency is mentioned.
Prescription Requirement: Medical Oversight Recommended for Peptide Selection
The speaker concludes by directing viewers to seek a medical team for proper prescription and individualized selection between Selank and Semax. This implies the compounds require or benefit from professional oversight rather than self-directed use. No safety contraindications are explicitly detailed.
Route of Administration: Both Peptides Available as Nasal Spray
The speaker references nasal spray as the delivery format for both Selank and Semax, implying intranasal administration is the standard or preferred route discussed in this context. No specific dosage, concentration, or spray frequency is mentioned.
Pre-Optimization Protocol: Address Sleep and Inflammation Before Peptide Use
The speaker recommends resolving sleep issues and systemic inflammation as foundational steps before introducing either Selank or Semax. This is framed as a prerequisite to ensure the peptides function as precision tools rather than expensive guesses. No specific sleep or inflammation protocols are detailed.
Stacking Selank and Semax Together: Cautionary Recommendation Against Default Stacking
The speaker explicitly cautions against stacking both Selank and Semax by default, stating that doing so may result in paying for a signal the user does not need. The recommendation is to identify the specific cognitive gap first and use only the peptide that addresses it. No dosage information is provided.
Selank vs. Semax: Symptom-Matched Selection Protocol
The speaker argues that Selank and Semax address opposite cognitive bottlenecks — low arousal/fog versus high arousal/anxiety — and that users should select only the compound matching their specific problem. The framing is that the two peptides are not interchangeable or redundant, and choosing incorrectly wastes money on an unneeded signal.
Selank Mechanism: Anxiolytic Effect Without Sedation
Selank is described as reducing anxiety without causing sedation, producing a state of calm without cognitive slowing. It is positioned as the appropriate tool when the user experiences a wired, racing mind. No dosage or frequency is mentioned.
GHK-Cu: The Peptide Everyone Is Injecting (Big Mistake?)
Regulatory status update affecting Selank. The host reviews the FDA 503A bulk drug substances list and notes that in a September 2024 settlement with compounding pharmacy trade groups, five peptides - CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604 and Selank - were referred to the Pharmacy Compounding Advisory Committee for review. In each case the FDA recommended against inclusion on the allowed list and the PCAC voted against them. The practical point for Selank is that going through the PCAC process does not guarantee a favorable outcome, so compounded Selank remains restricted even as RFK Jr's February 27 2026 statements suggest roughly 14 of the 19 category two peptides may move back to category one. No federal register notice has been issued, and the FDA has represented that a final rule is expected no later than March 2027. This is regulatory commentary from a physician, not clinical evidence on Selank.
It is Official: 7 Life-Changing Peptides are BACK.
Overview of the FDA/PCAC peptide landscape. Describes Semax (as C-Max) as a stroke-recovery/cognitive agent, Selank as a non-sedating anxiolytic, and Dihexa as a potent synaptogenic compound (technically not a peptide). Context on the 2023 gray-market shift and PCAC scheduling.
The FDA Could Ban These 7 Peptides Forever
Regulatory update on the FDA PCAC hearing (July 23-24, 2026) reviewing seven peptides including Dihexa and Selank (with BPC-157, TB-500, KPV, MOTS-c, Epitalon). Briefing documents lean against approval; creator is petitioning to speak and urges public comment. Relevant to future legal access for Dihexa and Selank.
The Real Reason Antidepressants Do not Work for Anxiety (and the solution) - Dr Trevor Bachmeyer
Argues Selank works where SSRIs fail by upregulating receptors rather than flooding neurotransmitters. Cites Russian studies: increased GABA-A receptor density in hippocampus/PFC (Kozlovskaya 2014, Biol Psychiatry), enhanced 5-HT1A binding in dorsal raphe (2011), raised dopamine in nucleus accumbens/PFC (2012). Expert opinion citing animal/human work.
Selank for the Central Stress and Mental-Health Component of Chronic Neuropathy
Clinician describes using Selank alongside stellate ganglion blocks and IV CBD to address the central stress and mental-health component of chronic neuropathy when local nerve pain cannot be fully resolved. Positions Selank as targeting the stress/anxiety axis that amplifies central pain rather than the peripheral lesion.
Low-and-Titrate Dosing Philosophy for Selank
The practitioner applies a conservative start-low-and-titrate approach when initiating Selank therapy, beginning with a single spray and evaluating the patient's response before adjusting. This reflects a general clinical philosophy of individualized dosing rather than a standardized fixed protocol.
Selank Immune Modulation Properties
The practitioner highlights Selank's immune-modulating qualities as a notable and valued benefit of the peptide, describing them as 'awesome.' No specific immune mechanisms or clinical details are elaborated upon in this segment, but it is cited as a distinct reason for recommending Selank.
Selank for Sleep Support
Selank may assist with sleep by calming mental activity, though the practitioner explicitly clarifies it does not directly induce sleep. Its anxiolytic properties appear to be the mechanism by which it supports sleep onset, making it a secondary rather than primary sleep aid.
Selank Route of Administration Comparison: Spray vs. Injectable
Selank is available in both nasal spray and subcutaneous injectable forms. The injectable route requires a significantly lower dose (up to 300 mcg) compared to the spray (up to 750 mcg) to achieve equivalent effects, implying higher systemic bioavailability via injection. The spray is noted as more convenient for users despite the higher dose requirement.
Selank Subcutaneous Injection Dosing Protocol
When administered via subcutaneous injection, Selank requires a lower dose of up to 300 micrograms compared to the nasal spray route. The practitioner states that injectable Selank is equally effective at this lower dose, suggesting improved bioavailability via injection versus intranasal delivery.
Selank Nasal Spray Dosing Protocol
Selank administered via nasal spray has a suggested daily usage of up to 750 micrograms total. The practitioner recommends starting with one spray initially, following a low-and-titrate approach to assess individual response before increasing dose.
Selank for Anxiety Management
Selank is described as an effective peptide for managing anxiety, with the practitioner noting it as one of their first-choice peptides for this indication. Patients reportedly experience better emotional control and clarity of thought over the course of a week. The practitioner assesses efficacy by having patients reflect on how they handled the week overall.
Selank for Sleep & Anxiety via GABA Activation
Fitness/biohacking channel discusses Selank's mechanism: improves GABA activation for parasympathetic mode, beneficial for anxious individuals with racing thoughts at bedtime. Positions Selank as a sleep-support peptide for those with naturally high anxiety. No primary research cited.
Selank as a Normalizing Agent Rather Than a Unidirectional Brain Chemistry Modifier
The speaker characterizes Selank's overarching mechanism as one of normalization rather than directional pharmacological push. Unlike traditional anxiolytics or cognitive enhancers that force brain chemistry in a single direction, Selank is described as helping restore balance across multiple neurochemical systems. This framing positions it as both an anxiolytic and a cognitive peptide with a broad homeostatic mechanism.
Selank Modulates BDNF and Neuroprotective Peptides to Support Neuroplasticity
Research referenced by the speaker suggests Selank can modulate levels of brain-derived neurotrophic factor (BDNF) and other neuroprotective peptides. This modulation is said to support synaptic function and cognitive processing, particularly under conditions of stress. No specific study type, dosage, or quantitative BDNF change is cited.
Selank Normalizes HPA Axis Function and Stress Response
Selank is described as acting on the hypothalamic-pituitary-adrenal (HPA) axis, the body's core stress management system. Dysregulation of the HPA axis is associated with chronic cortisol elevation, poor stress tolerance, and anxiety. Selank appears to help normalize HPA axis function, leading to a more appropriate and balanced stress response.
Selank Modulates GABAergic Activity and Serotonin Signaling for Anxiolytic Effects
Selank influences two key neurotransmitter systems: GABA (the brain's primary inhibitory neurotransmitter) and serotonin (involved in mood, anxiety, and social behavior). It is reported to increase GABAergic activity and help balance serotonin signaling. Notably, the speaker claims this occurs without the sedation or tolerance development associated with traditional anxiolytic medications.
Three-Domain Peptide Protocol Framework for Perimenopausal Women
The speaker outlines a structured three-domain framework for peptide use in perimenopausal women: (1) metabolic system — tirzepatide or retatrutide for weight and appetite control; (2) sleep quality — selank or DSIP for anxiety and sleep; (3) growth hormone axis — tesamorelin or CJC-1295 for GH support. This represents the only explicit stacking/protocol structure in the video. No dosages, frequencies, or cycling protocols are provided for any of the three domains.
Peptides as Symptomatic Layer Only — Not a Root-Cause Fix for Perimenopause
The speaker makes a broad protocol-level finding that all peptide interventions in perimenopause are symptomatic management tools and should only be introduced as a 'second layer' after the underlying hormonal deficiency (progesterone first, then estrogen) has been addressed. Using peptides without correcting the progesterone-estrogen ratio is characterized as insufficient. This represents a stacking and sequencing recommendation applicable to all peptides discussed in the video.
Selank for Anxiety and Sleep Quality in Perimenopause
Selank is recommended to address perimenopause-related anxiety and sleep disruption. The speaker identifies anxiety and poor sleep as downstream consequences of the progesterone-estrogen ratio imbalance. No dosage, route of administration, or frequency is specified. It is presented as a symptomatic intervention rather than a hormonal solution.
Selank evidence limited to Russian clinical trials
All human clinical data on Selank comes from Russian studies. There are no published Western clinical trials as of the video's recording. Sample sizes are smaller than what would typically be required for FDA approval. The speaker acknowledges the evidence is promising but notes this limitation in evidence depth compared to more established compounds.
Selank safety profile and contraindications
Selank has a minimal side effect profile. The most common side effects are mild nasal irritation from the spray and occasional mild headache. No sedation, cognitive impairment, or motor coordination effects are reported. Contraindications include pregnancy/breastfeeding, concurrent use of MAO inhibitors, and uncontrolled psychiatric conditions such as mania. Long-term safety data is not fully established by Western standards.
Selank dosage protocol: 150-300 mcg intranasal 2-3x daily, cycled
Selank is primarily administered intranasally (nasal spray or drops) as it crosses the blood-brain barrier directly through nasal passages. Subcutaneous injection is also possible for more precise dosing. Oral administration is not viable due to stomach acid degradation. Typical dosing is 150-300 micrograms intranasally, two to three times per day, with protocols running 2-4 weeks on followed by 2-4 weeks off.
Selank derived from Tuftsin by adding three amino acids
Selank is a seven amino acid peptide derived from Tuftsin, a naturally occurring four amino acid fragment of human immunoglobulin G (IgG). Researchers at the Institute of Molecular Genetics at the Russian Academy of Sciences in the 1990s extended Tuftsin by three amino acids to improve stability and blood-brain barrier penetration. The result retained Tuftsin's immune modulating properties while gaining anxiolytic effects.